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      Amendments from Version 1
We have responded to reviewer comments by making clear that 
we have measured the prevalence of impaired renal function, 
defined by one measure of eGFR, as opposed to chronic kidney 
disease which requires two measures more than 3 months apart. 
We have also discussed in more depth the need for better studies 
to determine the prevalence of renal disease across sub-Saharan 
Africa. We have also made minor corrections to the paper and 
supplementary tables.
See referee reports
REVISED
Introduction
Chronic kidney disease (CKD) is an under-recognized non-
communicable disease, associated with a high morbidity and 
mortality. It is estimated that one in ten people are living with 
kidney disease worldwide and the prevalence may be higher in 
low-income countries such as Uganda1,2. However, as shown in a 
recent systematic review the quality of data is often poor, 
frequently using convenience samples in high-risk populations3. 
Furthermore, only 2% of the studies included in this review used 
the CKD-EPI formula for calculation of estimated glomerular 
filtration rate (eGFR) which, based on limited data, has been 
found to be the best estimate of population CKD prevalence3,4. 
Community-based studies of the prevalence of impaired renal 
function have shown marked variation in results. Among peo-
ple living with HIV/AIDS, estimates range from 0.7% in Rakai, 
Central Uganda, 14.4% in Gulu, Northern Uganda, 26.5% in 
Zambia to 41.3% in Tanzania5–8. Among HIV-negative popula-
tions, estimates range from 2.5% in Wakiso, Central Uganda to 
26.5% in Tanzania8,9. Hospital-based studies from a National 
Referral Hospital in Uganda show that most patients with kidney 
disease are young and have advanced disease by the time of 
presentation10. Thus, in sub-Saharan Africa estimates of kidney 
disease prevalence vary widely depending on the methods 
used to determine renal function and the population studied, in 
particular the age distribution8,11–19.
Globally, among the known key risk factors for CKD are 
diabetes mellitus, hypertension and infections such as HIV. 
Hypertension and HIV are important problems in Uganda with 
hypertension prevalence estimated to be 26.4%20 and rising 
among those with HIV-infection21. However, the prevalence of 
diabetes mellitus is low compared to high-income countries at 
2%22. Moreover, some studies have also highlighted differences 
in the prevalence of impaired renal function between urban 
and rural areas in Africa. A study from Cameroon found the 
overall prevalence of CKD to be 13.2%: 14.1% and 10.9% among 
rural and urban dwellers, respectively23. Late diagnosis, along 
with limited heath care leading to poor control of hypertension 
and diabetes may be possible drivers of a higher prevalence in 
rural populations.
Therefore, we aimed to determine the prevalence and associa-
tions of impaired renal function among a representative sample 
of a rural area of Uganda, within an existing population cohort 
using high quality sampling methods.
Methods
Study design and setting
The General Population Cohort (GPC) was established in 1989, 
by the United Kingdom Medical Research Council and the 
Uganda Virus Research Institute, in Kalungu District, South-
western Uganda24. The cohort was initially established to 
examine prevalence, incidence, risk factors and trends of infec-
tion with HIV in a rural African population. More recently, 
research activity has broadened to include the epidemiology 
and genetics of other communicable and of non-communicable 
diseases, including cancer, cardiovascular disease and diabe-
tes24,25. In brief, the GPC is a community-based open cohort 
study of residents of 25 neighbouring villages within one-
half of a sub-county, lying about 40 km from Lake Victoria. 
The population is scattered across the countryside in villages 
defined by administrative boundaries, with a few concentrated 
in small trading centres. The population under survey includes 
approximately 22,000 people, less than half of whom are more 
than 13 years of age. The cohort is dynamic with new births, 
deaths and migration reported at each round of follow-up. Data 
are collected through an annual census, an annual question-
naire and serological survey from 1989–2011 and a biennial 
questionnaire and serological survey thereafter. Details of sexual 
behaviour, medical, sociodemographic and geographic factors 
are recorded. Blood specimens are obtained at each biennial 
survey. Serum is tested for HIV-1 and the remainder is stored at 
-80°C. Since 1989, the seroprevalence of HIV has remained 
relatively stable in this population, with about 8% of participants 
infected; in recent years, prevalence has risen slightly, with the 
roll out of antiretroviral therapy and consequent improvements 
in survival.
Variables used for analysis were extracted from two separate 
survey rounds of the GPC (2011–2012 and 2014–2015), and 
participants’ information gathered from questionnaire and 
laboratory data of the survey rounds were linked by unique 
identifiers. For adults (18+ years for males and 16+ years for 
females), variables used to develop a socioeconomic score 
(SES), smoking status, alcohol consumption, fruit and vegetable 
intake and results of Hepatitis B and C tests were derived 
from the 2011–2012 survey round. Variables associated with 
participant’s eGFR, age, maximum education level, current 
marital status, history of stroke, body mass index (BMI) and HIV 
status were based on the 2014–2015 survey round.
Data collection
Data collected from the GPC questionnaire regarding sexual 
behaviour and lifestyle factors were self-reported (Supplementary 
File 1). Anthropometric measurements and blood tests were 
performed by trained interviewers/nurses using calibrated 
instruments and following standard operating procedures. 
We adapted the World Health Organization (WHO) STEP-
wise approach to surveillance questionnaire to obtain socio- 
demographic characteristics, lifestyle (diet, tobacco, and alcohol 
consumption), medical history and biophysical measurements. 
Blood pressure was measured using a digital sphygmomanom-
eter (Omron M4-1). The participant had to be in a sitting position 
and the mean of the second and third readings taken at 5-minute 
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intervals was used for analysis. Body weight was measured using 
the Seca 761 mechanical scales and body height was measured 
using a stadiometer to the nearest 1 kg and 0.1 cm, respectively. 
Both scales were calibrated according to manufacturer guidelines 
weekly.
Laboratory tests
Blood tests for haemoglobin, HIV screening, HbA1c, hepatitis 
B and C viruses, as well as the creatinine level were performed. 
Venous blood was tested for haemoglobin level using CT -5 
Coulter Ac.T 5diff AL (Autoloader) [Beckman Coulter, North 
America]. HIV testing was performed using an approved national 
algorithm26. Hepatitis B surface antigen, Hepatitis C antibody 
and creatinine level were tested using a Cobas e 601 Auto 
Analyzer (Roche Diagnostics, North America). Creatinine was 
measured using the enzymatic method traceable to an isotope 
dilution mass spectrometry method27. The MRC/UVRI Entebbe 
laboratories currently have laboratory accreditation through ISO 
15189 of the Kenya Accreditation Service, and are enrolled in 
external quality control programs for South Africa, America, 
Australia and the United Kingdom.
Definitions and classification
Each participant’s SES was derived from conducting principal 
component analysis (PCA) using variables relating to household 
infrastructure and property ownership. Urbanicity score used in this 
study was derived from a previous study using information from the 
Round 22 survey28. BMI was classified according to WHO catego-
ries (weight/height2: kg/m2): underweight (<18.5 kg/m2), normal 
weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2) and obese 
(>30.0 kg/m2). Blood pressure (BP) classification was derived 
from the National Institute of Health guidelines: Pre-Hyperten-
sion was defined as having a systolic BP greater than 120mmHg 
but less than 140 mmHg, and a diastolic BP greater than 80 
mmHg but less than 90 mmHg. Hypertension was defined as hav-
ing a diastolic BP greater than or equal to 90 mmHg, systolic BP 
greater than or equal to 140 mmHg or being on treatment for 
high BP. Anaemia was defined as having haemoglobin levels 
less than 130 g/l in men, 120 g/l in non-pregnant women, and 
110 g/l in pregnant women. Diabetes mellitus was diagnosed by 
either having HbA1c >6.5%, through self-reported measures of 
being previously diagnosed with diabetes, or by current treatment 
for diabetes.
Classification of renal function
The estimated glomerular filtration rate (eGFR) was calculated 
using the CKD-Epi formula, without use of the coefficient 
for African Americans29. Impaired renal function was divided into 
five categories analogous to CKD stages, based on the National 
Kidney Foundation guidelines (without including proteinuria) 
as: normal eGFR (q90 ml/min/1.73 m2); low eGFR (60–89 ml/
min/1.73 m2); moderately reduced eGFR (30–59 ml/min/1.73 m2); 
severely reduced eGFR (15–29 ml/min/1.73 m2); and kidney 
failure (eGFR <15 ml/min/1.73 m2)30.
Statistical analysis
Baseline characteristics were tabulated stratified by sex. The 
prevalence of impaired renal function was also age standardised 
using the WHO world population as the reference.
We used logistic regression to estimate odd ratios (OR), along 
with its 95% confidence intervals (95% CIs), to identify potential 
factors independently associated with CKD. A forward step-
wise approach was used in developing our multivariable model 
adjusting for age, sex, and all independent predictors of CKD.
We also conducted a secondary analysis to compare partici-
pants with eGFR<60 ml/min/1.73 m2 to those with normal renal 
function excluding individuals in the low eGFR category. The 
population attributable fraction (PAF) of impaired renal function 
was estimated for hypertension, and anaemia using the adjusted 
odds ratios from the final multivariable model.
All statistical analyses were performed using STATA 13 SE 
(Stata Corp, Texas, USA).
Ethical considerations
All study participants gave written informed consent to 
participate in the study. The study was approved by Uganda Virus 
Research Institute Research and Ethics Committee (UVRI-REC) 
and the Uganda National Council for Science and Technology 
(UNCST).
Results
Baseline characteristics of study participants
A total of 6,397 individuals participated in the Round 24 GPC 
survey in 2014–2015 and 5,979 (93.5%) individuals had valid 
creatinine test results. The average age of study participants 
was 39 years (range: 16 years to 103 years), consisting of 3,626 
(60.7%) females. The majority of patients had primary-level 
education (60.4%). HIV prevalence was 9.7% (males: 8.4%, 
females: 10.5%) within this study population, and about 40% 
of the population was classified as pre-hypertensive. The mean 
serum creatinine level of the study population was 66.3 mmol/l 
(95% CI 65.4–66.3), and using the CKD-EPI equation, the 
average eGFR was 109.3 ml/min/1.73 m2 (95% CI 108.8–109.9) 
(Table 1).
Prevalence of impaired renal function
The overall prevalence of eGFR <60 ml/min per 1.73 m2 was 
1.6% (95% CI 1.34–1.99). Of the respondents, 4,792 (80.2%) were 
classified as normal, 1,089 (18.2%) as low eGFR, 91 (1.5%) as 
moderately reduced eGFR, 4 (0.1%) as severely reduced eGFR, 
and 3 (0.1%) classified as having kidney failure (Figure 1, 
Table 2). The prevalence of impaired renal function among those 
over the age of 16, age-standardised to the WHO population, was 
1.8%.
Factors associated with eGFR <60 ml/min per 1.73 m2
Age and sex adjusted associations with the presence of eGFR 
<60 ml/min per 1.73 m2 are shown in Supplementary Table 1. In 
multivariable analysis, older age, hypertension (OR 2.86; 95% 
CI 1.15-7.08) and anaemia (OR 2.14 ; 95% CI 1.12-4.09) were 
independently associated with eGFR <60 ml/min per 1.73 m2 (Table 3).
Age and sex adjusted associations of variables with the presence 
of eGFR of <90 mls/min/1.73m2 are shown in Supplementary 
Table 2. In multivariable analysis, female sex (OR 1.56, 95% 
CI 1.27-1.93); older age, higher urbanicity score, being overweight 
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Table 1. Characteristics of participants with creatinine results 
from Survey round 24 among a general population cohort in 
rural Uganda (N=5,979).
Variable Male, n (%) Female,  
n (%)
Total, n (%)
Age Group
<35 1,033 (43.90) 1,703 (46.97) 2,736 (45.77)
35–44 460 (19.55) 721 (19.88) 1,181 (19.74)
45–54 378 (16.02) 507 (13.98) 884 (14.79) 
55–64 244 (10.37) 336 (9.27) 580 (9.70) 
65–74 138 (5.86) 231 (6.37) 369 (6.17) 
75+ 101 (4.29) 128 (3.53) 229 (3.83) 
Max Education 
None 137 (5.82) 394 (10.87) 531 (8.88) 
Primary 1,488 (63.24) 2,122 (58.52) 3,610 (60.38) 
Secondary 570 (24.21) 946 (26.09) 1,516 (25.35) 
Higher Level 158 (6.71) 164 (4.52) 322 (5.38) 
Currently Married**
No 357 (20.62) 1,075 (36.68) 1,432 (30.72) 
Yes 1,373 (79.36) 1,856 (63.32) 3,229 (69.28) 
Urbanicity*1 
Quartile 1 513 (28.71) 756 (26.31) 1,259 (27.24) 
Quartile 2 468 (26.19) 733 (25.86) 1,201 (25.98) 
Quartile 3 436 (24.40) 697 (24.59) 1,133 (24.51) 
Quartile 4 370 (20.71) 659 (23.25) 1,029 (22.26) 
SES*2 
Lower 565 (35.76) 819 (32.79) 1,384 (33.94) 
Middle 521 (33.04) 833 (33.35) 1,354 (33.23) 
Upper 493 (31.20) 846 (33.87) 1,339 (32.83) 
BMI3** 
Normal weight 1,786 (76.47) 2,290 (65.84) 4,076 (70.11) 
Underweight 407 (17.42) 302 (8.68) 709 (12.19) 
Overweight 122 (5.22) 648 (18.63) 770 (13.24) 
Obese 21 (0.90) 238 (6.84) 259 (4.45) 
Blood Pressure*4 
Normal 668 (40.44) 1,235 (48.82) 1,903 (45.51) 
Pre-Hypertension 719 (43.52) 944 (37.28) 1,663 (39.75) 
Hypertension 265 (16.04) 352 (13.90) 617 (14.75) 
Variable Male, n (%) Female,  
n (%)
Total, n (%)
HIV Status** 
Negative 2,150 (91.57) 3,242 (89.51) 5,392 (90.32) 
Positive 198 (8.43) 380 (10.49) 578 (9.68) 
Hepatitis B* 
Negative 1,588 (96.48) 2,479 (98.10) 4,067 (97.46) 
Positive 58 (3.52) 48 (1.90) 106 (2.54) 
Hepatitis C* 
Negative 1,582 (96.17) 2,439 (96.52) 4,021 (96.38) 
Positive 63 (3.83) 88 (3.48) 151 (3.62) 
Anaemia*5 
Negative 1,078 (86.87) 1,583 (83.40) 2,661 (84.77) 
Positive 163 (13.13) 315 (16.60) 478 (15.23) 
Diabetes*6 
No 1,603 (97.74) 2,467 (97.94) 4,070 (97.53) 
Yes 37 (2.26) 52 (2.06) 89 (2.14) 
Current smoking status* 
Not current smoker 1,301 (78.80) 2,478 (97.87) 3,779 (90.34) 
Non-daily smoker 83 (5.03) 17 (0.67) 100 (2.39) 
Daily smoker 267 (16.17) 37 (1.46) 304 (7.27) 
Alcohol consumption* 
Never drinkers 831 (54.64) 1,589 (69.27) 2,420 (63.43) 
No alcohol in past 
30 days 
90 (5.92) 250 (10.90) 340 (8.91) 
Alcohol in past 30 
days 
600 (39.45) 455 (19.83) 1,055 (27.65) 
*Variables from a previous round (R22) of the GPC where total number of 
participants may vary: Urbanicity (n=4,622), SES (n=4,077), Blood Pressure 
(BP) (n=4,184), Hepatitis B (n=4,173), Hepatitis C (n=4,172), smoking 
status (n=4,183), alcohol consumption in the last 30 days (n=3,815), and 
anaemia (n=3,139). 1Urbanicity score derived from Riha et al. (2014). 
2Socio-economic Score (SES) derived from conducting Principle Component 
Analysis (PCA) on a statistical software using variables relating to household 
infrastructure and property ownership 3Body Mass Index (BMI) Classification 
according to WHO (weight/height2: kg/m2): Underweight (<18.5 kg/m2), 
Normal weight (18.5–24.99 kg/m2), Overweight (25.0–29.99 kg/m2), Obese 
(>30.0 kg/m2). 4BP classification derived from the National Institute of Health 
guidelines: Pre-Hypertension was defined as having a systolic BP >120 
mmHg but <140 mmHg, and a diastolic BP >80 mmHg but <90 mmHg. 
Hypertension was defined as having a systolic BP q90 mmHg, diastolic BP 
q140 mmHg. 5Anaemia was defined as having haemogloblin levels less than 
130 g/L in men, 120 g/L in non-pregnant women, and 110 g/L in pregnant 
women. Only 2,064 individuals had anaemia results from the R24 of the GPC
6Diabetes was defined as having HbA1C >6.5%, or being previously 
diagnosed with diabetes, or are currently on treatment for diabetes. 
**Variables in R24 with missing individuals: Currently Married (n=4,661), BMI 
(n=5,814), HIV (n=5,970)
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Figure 1. Prevalence of estimated glomerular filtration rate <60 ml/min/1.73 m2 by age group among a rural Ugandan cohort.
Table 2. Mean serum creatinine and categories of estimated glomerular 
filtration rate (eGFR) in the general population cohort.
Variables Mean (95% CI)
Measurements
Serum creatinine (mg/dl) 0.75 (0.74–0.75)
eGFR (ml/min/1.73m2)
   CKD-EPI equation*1 109.3 (108.8–109.9)
   MDRD equation* 106.2 (105.4–107.1)
Individuals n(%)
Category of level of eGFR
Normal eGFR (q90 ml/min per 1.73 m2) 4,792 (80.15)
Low eGFR (60–89 ml/min per 1.73 m2) 1,089 (18.21)
Moderately reduced eGFR (30–59 ml/min per 1.73 m2) 91 (1.52)
Severely reduced eGFR (15–29 ml/min per 1.73 m2) 4 (0.07)
Kidney Failure (eGFR <15 ml/min per 1.73 m2) 3 (0.05)
*The CKD-EPI eGFR calculations were used as the primary outcomes in this study; the 
MDRD equation was used to contrast the difference between the two equations. 1The 
coefficient for black race was omitted while using this equation.
or obese; having hypertension (OR 1.60, 95 % CI 1.22-2.11) and 
HIV-positive status (OR 1.55, 95% CI 1.13-2.04) were associated 
with impaired kidney function (Supplementary Table 3).
Comparison of participants with eGFR <60 ml/min/1.73m2 to 
those with eGFR >90 ml/min/1.73m2 revealed that older age, 
hypertension and anaemia were independently associated with 
impaired renal function (Supplementary Table 4).
The adjusted population attributable fraction of decreased 
renal function attributable to hypertension and anaemia was 
26.4% and 12.8%, respectively.
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Table 3. Final multivariable model of factors 
independently associated with estimated glomerular 
filtration rate <60 ml/min per 1.73m2.
Variable Adjusted OR (95% CI)1
Sex P=0.56
Male Reference
Female 1.19 (0.64–2.24)
Age Group P<0.001
<35 Reference
35–44 0.53 (0.05–5.14)
45–54 3.49 (0.86–14.09)
55–64 5.73 (1.47–22.25)
65–74 12.24 (3.27–45.82)
75 + 29.68 (7.99–110.19)
Blood Pressure*2 P=0.05
Normal Reference
Pre-Hypertension 1.92 (0.81–4.57)
Hypertension 2.86 (1.15–7.08)
Anaemia3 P=0.02
Negative Reference
Positive 2.14 (1.12–4.09)
*Variables from a previous round (R22) of the GPC where total 
number of participants may vary: Blood Pressure (n=3,039). 
1Multivariable model adjusted for age, sex and all independent 
predictors of eGFR <60mls/min per 1.73 m2. OR, odds ratio; 95% CI, 
95% confidence interval. 2Blood pressure classification derived from 
the National Institute of Health guidelines: Pre-Hypertension was 
defined as having a systolic blood pressure greater than 120 mmHg 
but less than 140 mmHg, and a diastolic blood pressure greater 
than 80 mmHg but less than 90 mmHg. Hypertension was defined 
as having a systolic blood pressure (BP) greater than or equal to 
90mmHg, diastolic BP greater than or equal to 140mmHg. 3Anaemia 
was defined as having haemoglobin levels less than 130 g/l in men, 
120 g/L in non-pregnant women, and 110 g/l in pregnant women. 
Only 2,064 individuals had anaemia results from the R24 of the GPC
Discussion
We found a prevalence of eGFR <60 mL/min per 1.73 m2 of 
1.64% in this predominantly young rural community of Uganda 
with more than one-fifth of the study participants having eGFR 
<90 mL/min per 1.73 m2. Impaired renal function was strongly 
associated with age, high blood pressure and anaemia.
Comparing different prevalence estimates of impaired renal 
function from studies across sub-Saharan Africa is challeng-
ing for many reasons. In a meta-analysis of CKD in sub-Saharan 
Africa by Stanifer et al.3 the overall prevalence was 13.9% but the 
majority of the studies were conducted among patients with 
known risk factors for renal disease such as diabetes mellitus, 
HIV infection and hypertension. Furthermore, only 2% of the 
included studies used the CKD-EPI formula for calculation of 
eGFR although, based on limited data, it has been found to be the 
best estimate of population CKD prevalence3,4. The age structure 
of population varies widely between countries in sub-Saharan 
Africa making standardisation to a reference population crucial 
for comparisons between regions or countries. In addition, the 
prevalence of risk factors such as HIV infection vary substantially 
across and within countries.
We found that older age, hypertension and anaemia were associ-
ated with impaired renal function. Age is known to be strongly 
associated with eGFR3,23,29. Hypertension is both a cause and 
a consequence of kidney disease, and in this cross-sectional 
survey it was not possible to tell whether the participants had 
hypertension as a cause or consequence of the kidney disease. 
However there has been a rise in reported levels of hyperten-
sion in Uganda, from 13.7%31 in 1969 to 26.4% in 201520. 
Anaemia is also often a consequence of kidney disease, or may 
be due to shared risk-factors such as other chronic diseases. We 
found that anaemia was associated with kidney disease, even 
for patients with eGFR <90 ml/min/1.73m2, a level of kidney 
function at which a direct causal effect would not be anticipated. 
Factors which have been traditionally associated with kidney 
disease in high-income countries such as smoking, alcohol 
intake and obesity were not associated with the presence of 
eGFR <60 mL/min per 1.73 m2 in this population. This may be 
because of the low prevalence of these factors in the community, 
or may suggest that the risk factors for CKD are different in this 
region. Indeed, other researchers have found that the majority 
of kidney disease in SSA is not explained by traditional risk 
factors32.
Study strengths and limitations
This was a large community-based study conducted within a 
well-characterized population cohort. We used the CKD-Epi 
formula to determine eGFR, which is thought to be the best 
estimate of true GFR in sub-Saharan Africa. We measured 
a wide range of social and anthropometric factors, chronic 
diseases and biochemical measurements in a structured and 
validated manner. In addition, our prevalence estimates have 
been standardized to the WHO population to enable comparability 
with other studies across the world.
However, there were limitations, including lack of screening for 
urine abnormalities (proteinuria and hematuria) which could have 
led us to underestimate the prevalence of kidney disease. Newer 
classifications of CKD require measurement of proteinuria to 
define kidney disease4. We only measured creatinine on one occa-
sion while two results of eGFR <60 mL/min per 1.73 m2 more than 
3 months apart are required for the formal definition of CKD. 
This may have led to an overestimate of the prevalence of 
impaired renal function. However, most large scale epide-
miological surveys have use one measurement of creatinine33. 
In addition, our study was prospectively sampled from well 
people and are thus likely to be affected by a transient fall in 
eGFR associated with acute illness. This is in contrast to many 
studies using routinely collected data to define renal function 
where misclassification is likely if blood tests are measured 
during when patients are unwell34. Even if we had two measures 
of creatinine we would not have been able to confidently assert 
that patients with eGFR <60 mL/min per 1.73 m2 had ‘chronic 
kidney disease’ as the estimating equations are not validated in 
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sub-Saharan Africa and the long-term outcome implications, on 
which the CKD categorisation was defined, are not yet understood 
in this setting.
Implications of the study
Interventions for end-stage renal disease are currently limited for 
most countries in sub-Saharan Africa with very poor access to 
dialysis and kidney transplantation9,35. This study has established 
a significant prevalence of impaired renal function, highlighting 
the need to focus efforts on preventive strategies to delay 
onset and slow progression of renal disease. However, marked 
uncertainty remains about how best to estimate GFR in black 
Africans. This highlights the importance of our ongoing 
prospective study to determine the best way to measure renal 
function in sub-Saharan Africa: http://blogs.lshtm.ac.uk/ark/.
Conclusions
We found that approximately one in five adults in rural Uganda 
had impaired renal function despite a low prevalence of diabetes 
and obesity. Impaired renal function was strongly associated with 
high blood pressure and anaemia. More detailed studies are 
required to further determine specific risk-factors for impaired 
renal function and its progression.
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Supplementary Table 4. Final multivariable model of factors independently associated with CKD comparing individuals with estimated 
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Click here to access the data.
Supplementary File 1. GPC questionnaire regarding sexual behaviour and lifestyle factors.
Click here to access the data.
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